The Essentials of Clinical Dialysis. (Record no. 134121)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11175nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5183846 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729131648.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2017 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9789811011009 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9789811010996 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5183846 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5183846 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11480955 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1015885717 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC902-918 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 610 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Kim, Yong-Lim. |
| 245 14 - TITLE STATEMENT | |
| Title | The Essentials of Clinical Dialysis. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Singapore : |
| Name of producer, publisher, distributor, manufacturer | Springer Singapore Pte. Limited, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2017. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2018. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (280 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Preface -- Contents -- Contributors -- Part I: Preparation of Dialysis -- 1: Dialysis Indication and Initiation Time for Dialysis -- 1.1 Background -- 1.1.1 Kidney Functions -- 1.1.2 Historical Perspectives of the Timing of Dialysis Initiation -- 1.2 Current Considerations About Dialysis Initiation -- 1.2.1 Early Dialysis Initiation Is Not Favorable -- 1.2.2 The Initiating Dialysis Early and Late (IDEAL) Study -- 1.3 Factors To Be Considered for the Initiation of Dialysis -- 1.3.1 Uremic Symptoms -- 1.3.2 Nutritional Indications -- 1.3.3 Comorbidities -- 1.3.4 Speed of Decline of Renal Function -- 1.3.5 Facility Characteristics -- 1.3.6 Other Clinical Indicators -- 1.4 Published Guidelines -- 1.4.1 NKF KDOQI Guidelines -- 1.4.2 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline -- 1.4.3 Japanese Guidelines -- 1.4.4 European Best Practice Guidelines (EBPG) -- 1.4.5 Kidney Health Australia Caring for Australasians with Renal Impairment (KHA- CARI Guidelines) (Australia) -- 1.4.6 United Kingdom (The Renal Association) -- 1.4.7 The Canadian Society of Nephrology -- 1.5 Pre-dialysis Care -- 1.5.1 Vascular Access Existence of Initiation of Dialysis -- 1.6 Post-dialysis Initiation Management -- 1.6.1 Early Mortality -- 1.6.2 Importance of Pre-dialytic Care and Conservative Management -- 1.6.3 Incremental Dialysis -- References -- 2: Modality Selection -- 2.1 Introduction -- 2.2 Current Options, Characteristics of Dialysis Modalities, and Clinical Outcomes -- 2.2.1 Types and Characteristics of Dialysis Modalities -- 2.2.2 Comparison of Survival Outcomes by Dialysis Modality -- 2.2.3 Comparisons of Other Clinical Outcomes by Dialysis Modalities -- 2.3 Factors Influencing Decision-Making in Dialysis Modality Selection -- 2.4 Selection of Dialysis Modalities for Special Subgroups. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.4.1 Dialysis in the Elderly -- 2.4.2 Dialysis in Diabetic Patients -- 2.5 The Use of a Dialysis Decision Aid for Modality Choice -- References -- Part II: Hemodialysis -- 3: The Basics of Vascular Access Construction and Its Timing -- 3.1 Introduction -- 3.1.1 Informed Consent Related to the Construction and Restoration of VA -- 3.1.2 When to Construct the VA -- 3.1.3 Basics of VA Construction -- 3.1.3.1 Selecting the Type of VA -- 3.1.3.2 VA Construction (Surgery) -- Anesthesia of VA Construction -- Poor Fistula Maturation -- 3.1.3.3 VA Care Immediately Following Construction -- 3.1.3.4 Care Until Cannulation -- 3.1.3.5 Initiation of Cannulation -- 3.1.3.6 Precautions During HD -- 3.1.3.7 Procedures Following Dialysis Needle Removal -- 3.1.3.8 Long-Term Observation and Management of AVF and AVG (Ohira 2011) -- References -- 4: Hemodialysis Procedure and Prescription -- 4.1 Hemodialysis Procedure -- 4.1.1 Preparation of Items -- 4.1.2 Anticoagulation -- 4.1.3 Heparin Rinsing -- 4.1.4 Priming -- 4.1.5 Obtaining Vascular Access -- 4.1.5.1 Patients with Central Venous Catheter -- 4.1.5.2 Patients with Arteriovenous Fistula or Graft -- 4.1.6 Cannulation (Needling) -- 4.1.7 Complications of Cannulation -- 4.1.7.1 Infiltration -- 4.1.7.2 Thrombosis or Stenosis of Vascular Access -- 4.1.8 Initiating Hemodialysis -- 4.1.9 Monitoring of Parameters -- 4.1.9.1 Body Weight -- 4.1.9.2 Vital Signs -- 4.1.9.3 Pressure Monitors on the Arterial Blood Line -- 4.1.9.4 Pressure Monitors on the Venous Blood Line -- 4.1.9.5 Venous Air Trap and Detector -- 4.1.9.6 Food and Water Intake During Dialysis -- 4.1.10 Termination of Hemodialysis -- 4.1.11 Removing the Needle and Hemostasis -- 4.1.12 Post-dialysis Evaluation -- 4.2 Hemodialysis Prescription -- 4.2.1 Rationale for Hemodialysis Prescription. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.2.2 Basic Mechanisms Applied to Hemodialysis Prescription -- 4.2.2.1 Diffusion -- 4.2.2.2 Ultrafiltration -- 4.2.2.3 Convection -- 4.2.3 Parameters Related to Hemodialysis Prescription -- 4.2.3.1 Adequacy of Hemodial ysis -- 4.2.3.2 Ultrafiltration (Amount of Fluid Removal) -- 4.2.3.3 Dialysis Time and Frequency -- 4.2.3.4 Dialysate Sodium -- 4.2.3.5 Dialysate Potassi um -- 4.2.3.6 Dialysate Calcium -- 4.2.3.7 Dialysate Bicarbonate -- 4.2.3.8 Dialysate Magnesium -- 4.2.3.9 Dialysate Temperatu re -- 4.2.3.10 Dialysate Glucos e -- 4.2.3.11 Dialyzer -- 4.2.3.12 Blood Flow Rate -- 4.2.3.13 Dialysate Flow R ate -- 4.2.4 Hemodialysis Prescriptions in Patients with Residual Renal Function -- References -- 5: Technological Aspect for Hemodialysis -- 5.1 Introduction -- 5.2 Theatrical -- 5.2.1 Dialyzer Performance: Clearance (K) -- 5.3 Solute Removal Characteristics by Dialyzer -- 5.4 Kinetic Modeling for Blood Purification in Critical Care -- 5.5 Dialyzer Reuse -- 5.6 Evaluation for HD Treatment in Clinical -- 5.7 Internal Filtration -- 5.8 Biocompatibility and Quality for Dialysis Fluid -- 5.9 New Treatment Mode Using Ultrapure Dialysis Fluid -- References -- 6: Flux of Dialysis Membrane: Benefit and Risk -- 6.1 Introduction -- 6.2 Flux of Dialysis Membrane -- 6.3 Advances in Membrane Materials and Improvement in Flux (Water and Solute Permeability) -- 6.4 Changes in Targeted Uremic Toxins -- 6.5 Water Flux of Membrane -- 6.6 Risks Associated with High-Flux Membranes -- 6.6.1 Backfiltration of Pyrogens -- 6.6.2 Loss of Necessary Elements such as Albumin in the Body -- 6.7 Does High-Flux Membrane Contribute to Improving Survival? -- 6.8 Summary -- References -- 7: Anticoagulation -- 7.1 Anticoagulation for Hemodialysis -- 7.1.1 Introduction -- 7.1.2 Unfractionated Heparin (UFH). |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 7.1.3 Low-Molecular-Weight Heparin (LMWH) -- 7.1.4 Direct Thrombin Inhibitors -- 7.1.5 Regional Anticoagulation -- 7.1.6 Nafamostat Mesilate (NM) -- 7.1.7 Dose of Anticoagulant and Dialysis Vintage -- 7.1.8 Coagulation Due to Other Causes -- 7.1.9 Summary -- 7.2 Anticoagulation in Patients on Hemodialysis -- 7.2.1 Anticoagulation in Hemodialysis Patients -- 7.2.2 Mechanisms of Blood Coagulation and Coagulability Monitoring -- 7.2.2.1 Coagulation Cascade -- 7.2.2.2 Biological Reactions That Occur When the Coagulation Cascade Is Triggered By Contact with Dialysis Membrane -- 7.2.2.3 Coagulability Monitoring -- 7.2.3 Mechanisms of Actions and Usage of Each Anticoagulant During Hemodialysis Treatment -- 7.2.3.1 Unfractionated Heparin (UFH) -- 7.2.3.2 Low-Molecular-Weight Heparin (LMWH) -- 7.2.3.3 Nafamostat Mesilate: NM -- 7.2.3.4 Argatroban -- 7.2.4 Selection of the Appropriate Anticoagulant and Adjustment of Its Dose -- References -- 8: The Concept of Hemodialysis Adequacy and Kinetics -- 8.1 Introduction -- 8.2 Dialysis Prescriptions for Solute Removal -- 8.3 Solute Clearance -- 8.4 Solute Removal per Single Dialysis Session -- Kt/V -- 8.4.1 Removal of β2M (Middle Molecules) -- Appendix 1: Kinetics Modeling of Dialysis: Reference for JSDT Guideline (Watanabe et al. 2015) -- A. Indices -- Kt/Vurea -- Gotch and Sargent's Equation (Kt/Vurea) (Gotch and Sargent 1985) -- Daugirdas' Equation (Daugirdas 1989) -- Reduction Rate (RR) -- Solute Removal (M) -- Clear Space (CS) and CS Rate (CSR) -- Sampling Methods -- Clearance (CL) of Dialyzer -- References -- 9: Complications of Hemodialysis -- 9.1 Dialysis Reaction -- 9.1.1 Anaphylactic/Anaphylactoid Type (Life-Threatening Type) -- 9.1.1.1 Clinical Manifestations -- 9.1.1.2 Etiology and Pathogenic Mechanism -- 9.1.1.3 Management and Prevention -- 9.1.2 Nonspecific Type (Mild Type). |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 9.1.2.1 Clinical Manifestations -- 9.1.2.2 Etiology and Pathogenic Mechanism -- 9.1.2.3 Management and Prevention -- 9.2 Intradialytic Hypotension -- 9.2.1 Clinical Manifestations -- 9.2.2 Etiology and Pathogenic Mechanism -- 9.2.2.1 Humoral Factors -- 9.2.2.2 Vascular Factors -- 9.2.2.3 Cardiac Factors -- 9.2.3 Management -- 9.2.4 Preventive Measures for Controlling Humoral Factors -- 9.2.4.1 General Measures -- 9.2.4.2 Therapeutic Dialysis -- 9.2.5 Preventive Measures for Controlling Vascular Factors -- 9.2.5.1 Predialysis Antihypertensive Medication -- 9.2.5.2 Refraining from Food Intake During Dialysis -- 9.2.5.3 Bicarbonate Dialysate -- 9.2.5.4 Cool Temperature Hemodialysis -- 9.2.5.5 Drug Therapy -- 9.2.6 Preventive Measures for Controlling Cardiac Factors -- 9.2.6.1 Identification and Treatment of the Underlying Cardiac Diseases -- 9.2.6.2 Correction of Anemia -- 9.2.6.3 Use of High Calcium and Low Magnesium Dialysate -- 9.2.7 Stratified Approach to Prevent Intradialytic Hypotension -- 9.2.8 Resistant Intradialytic Hypotension -- 9.3 Other Common Complications -- 9.3.1 Postdialysis Fatigue Syndrome -- 9.3.2 Muscle Cramps -- 9.3.2.1 Clinical Manifestations -- 9.3.2.2 Etiology and Pathogenic Mechanism -- 9.3.2.3 Management and Prevention -- 9.3.3 Restless Leg Syndrome -- 9.3.3.1 Clinical Manifestations -- 9.3.3.2 Etiology and Pathogenic Mechanism -- 9.3.3.3 Management and Prevention -- 9.3.4 Nausea and Vomiting -- 9.3.4.1 Clinical Manifestations -- 9.3.4.2 Etiology and Pathogenic Mechanism -- 9.3.4.3 Management and Prevention -- 9.3.5 Headache -- 9.3.5.1 Clinical Manifestations -- 9.3.5.2 Etiology and Pathogenic Mechanism -- 9.3.5.3 Management and Prevention -- 9.3.6 Chest and Back Pain -- 9.3.7 Pruritus -- 9.3.7.1 Clinical Manifestations -- 9.3.7.2 Etiology and Pathogenic Mechanism. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 9.3.7.3 Management and Prevention. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Hemodialysis. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kawanishi, Hideki. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Kim, Yong-Lim |
| Title | The Essentials of Clinical Dialysis |
| Place, publisher, and date of publication | Singapore : Springer Singapore Pte. Limited,c2017 |
| International Standard Book Number | 9789811010996 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5183846">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5183846</a> |
| Public note | Click to View |
No items available.